Guía clínica de diagnóstico y tratamiento del prolactinoma y la hiperprolactinemia

Klibanski, 2010, Prolactinomas, N Engl J Med, 362, 1219, 10.1056/NEJMcp0912025 Fajardo-Montañana, 2009, Mutaciones de AIP en adenomas hipofisarios familiares y esporádicos: experiencia local y revisión de la literatura, Endocrinol Nutr, 56, 369, 10.1016/S1575-0922(09)72456-8 Melmed, 2011, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, 96, 273, 10.1210/jc.2010-1692 Casanueva, 2006, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas, Clin Endocrinol (Oxf), 65, 265, 10.1111/j.1365-2265.2006.02562.x Moreno, 2005, Guía clínica del manejo del prolactinoma y otros estados de hiperprolactinemia, Endocrinol Nutr, 52, 9, 10.1016/S1575-0922(05)70971-2 Petakov, 1998, Pituitary adenomas secreting large amounts of prolactin may give false low values in inmunoradiometric assays. The hook effect, J Endocrinol Invest, 21, 184, 10.1007/BF03347299 McKenna, 2009, Should macroprolactin be measured in all hyperprolactinaemic sera?, Clin Endocrinol (Oxf), 71, 466, 10.1111/j.1365-2265.2009.03577.x Gibney, 2005, The impact on clinical practice of routine screening for macroprolactin, J Clin Endocrinol Metab, 90, 3927, 10.1210/jc.2004-2234 Molitch, 2005, Medication-induced hyperprolactinemia, Mayo Clin Proc, 80, 1050, 10.4065/80.8.1050 Famini, 2011, Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients, J Clin Endocrinol Metab, 96, 1633, 10.1210/jc.2011-0168 Ikeda, 2010, Usefulness of composite methionine–positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma, J Neurosurg, 112, 750, 10.3171/2009.7.JNS09285 Ginovart, 2006, Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography, J Neurochem, 97, 1089, 10.1111/j.1471-4159.2006.03840.x Elston, 2009, Familial pituitary tumor syndromes, Nat Rev Endocrinol, 5, 453, 10.1038/nrendo.2009.126 Gillam, 2006, Advances in the treatment of prolactinomas, Endocr Rev, 27, 485, 10.1210/er.2005-9998 Schlechte, 1989, The natural history of untreated hyperprolactinemia: a prospective analysis, J Clin Endocrinol Metab, 68, 412, 10.1210/jcem-68-2-412 Webster, 1994, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group, N Engl J Med, 331, 904, 10.1056/NEJM199410063311403 Leong, 2000, CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas, Clin Endocrinol (Oxf), 52, 43, 10.1046/j.1365-2265.2000.00901.x Iyer, 2011, Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas, Endocr Pract, 17, e55, 10.4158/EP10369.CR Ono, 2008, Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients, J Clin Endocrinol Metab, 93, 4721, 10.1210/jc.2007-2758 Delgrange, 2009, Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients, Eur J Endocrinol, 160, 747, 10.1530/EJE-09-0012 Herring, 2009, Valvular heart disease and the use of cabergoline for the treatment of prolactinoma, Clin Endocrinol (Oxf), 70, 104, 10.1111/j.1365-2265.2008.03458.x Vallette, 2009, Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas, Pituitary, 12, 153, 10.1007/s11102-008-0134-2 Wakil, 2008, Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease, Eur J Endocrinol, 159, 11, 10.1530/EJE-08-0365 Valassi, 2010, Potential cardiac valve effects of dopamine agonists in hyperprolactinemia, J Clin Endocrinol Metab, 95, 1025, 10.1210/jc.2009-2095 Klibanski, 2009, Dopamine agonist therapy in prolactinomas: when can treatment be discontinued, J Clin Endocrinol Metab, 94, 2247, 10.1210/jc.2009-0999 Barber, 2011, Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy with prolactinoma occurs commonly specially in macroprolactinoma, Clin Endocrinol (Oxf), 75, 819, 10.1111/j.1365-2265.2011.04136.x Ciccarelli, 1997, Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumourous hyperprolactinaemia and outcome of drug-induced pregnancy, J Endocrinol Invest, 20, 547, 10.1007/BF03348017 Barker, 2003, Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume, J Clin Endocrinol Metab, 88, 4709, 10.1210/jc.2003-030461 Landolt, 1981, Surgical treatment of pituitary prolactinomas: postoperative prolactine and fertility in seventy patients, Fertil Steril, 35, 620, 10.1016/S0015-0282(16)45552-4 Soule, 1996, The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy, Clin Endocrinol (Oxf), 44, 711, 10.1046/j.1365-2265.1996.738559.x Babey, 2011, Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonist, Pituitary, 14, 222, 10.1007/s11102-010-0283-y Amar, 2002, Predictive value of serum prolactine levels measured immediately after transsphenoidal surgery, J Neurosurg, 97, 307, 10.3171/jns.2002.97.2.0307 Serri, 1983, Recurrence oh hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma, N Engl J Med, 309, 280, 10.1056/NEJM198308043090505 Massoud, 1996, Transsphenoidal adenomectomy for microprolactinomas: 10-20 years of follow-up, Surg Neurol, 45, 341, 10.1016/0090-3019(95)00430-0 Tanaka, 2010, Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas, World Neurosurg, 74, 147, 10.1016/j.wneu.2010.05.007 Brada, 2004, Radiosurgery for pituitary adenomas, Clin Endocrinol (Oxf), 61, 531, 10.1111/j.1365-2265.2004.02138.x De Rosa, 1998, Cabergolina treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptin, Eur J Endocrinol, 138, 286, 10.1530/eje.0.1380286 Molitch, 2010, Prolactinomas and pregnancy, Clin Endocrinol (Oxf), 73, 147 Bigazzi, 1979, A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments, J Clin Endocrinol Metab, 48, 9, 10.1210/jcem-48-1-9 Rigg, 1977, Pattern of increase in circulating prolactin levels during human gestation, Am J Obstet Gynecol, 129, 454, 10.1016/0002-9378(77)90594-4 Gonzalez, 1988, Pituitary gland growth during normal pregnancy: in vivo study using magnetic resonance imaging, Am J Med, 85, 217, 10.1016/S0002-9343(88)80346-2 Colao, 2008, Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study, Clin Endocrinol (Oxf), 68, 66, 10.1111/j.1365-2265.2007.03000.x Stalldecker, 2010, Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature, Pituitary, 1, 345, 10.1007/s11102-010-0243-6 Crosignani, 1992, Long term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women, Eur J Obs Gyn Rep Biol, 44, 175, 10.1016/0028-2243(92)90094-F Colao, 2010, Prolactinomas in children and adolescents, Endocr Dev Basel Karger, 17, 146, 10.1159/000262536 Karunakaran, 2001, The effect of the menopause on prolactin levels in patients with hyperprolactinaemia, Clin Endocrinol (Oxf), 54, 295, 10.1046/j.1365-2265.2001.01190.x Thapar, 2004, Proliferaty activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody, Neurosurgery, 61, 111 Katsas, 2005, Clinical review: diagnosis and management of pituitary carcinomas, J Clin Endocrinol Metab, 90, 3089, 10.1210/jc.2004-2231 Lim, 2006, Temozolomide: a novel treatment for pituitary carcinoma, Lancet Oncol, 7, 518, 10.1016/S1470-2045(06)70728-8 McCormack, 2009, Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours, Clin Endocrinol (Oxf), 71, 226, 10.1111/j.1365-2265.2008.03487.x Luque, 2011, Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas, J Pharmacol Exp Ther, 337, 766, 10.1124/jpet.110.177790 Lau, 2010, MGMT immunoexpression in aggressive pituitary adenoma and carcinoma, Pituitary, 13, 367, 10.1007/s11102-010-0249-0